This is one of the first peptide-based therapies for disc disease to reach human clinical trials, and its outcomes will significantly influence the field
Rather than focusing on quick fixes or stimulant-based solutions, GLP-1 therapy targets the biological systems that influence hunger and eating behaviors
For example, a patient with a normal baseline may have drug interrupted at 5 x ULN, whereas a patient with a baseline ALT of 2 x ULN will reach interruption at 7 x ULN, resulting in the degree of permitted ALT elevation before interruption being proportional to the baseline ALT value
The peptide is manufactured to ensure high purity , typically 95% , and is verified through standard analytical methods such as HPLC and mass spectrometry
Individual variation in response
GHRP-6 is less selective and raises appetite/cortisol more than ipamorelin